IDXX IDEXX Laboratories Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * MCKEON BRIAN P	2. Issuer Name and Ticker or Trading Symbol IDEXX LABORATORIES INC /DE [ IDXX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Executive VP & CFO
(Last)          (First)          (Middle) ONE IDEXX DRIVE	3. Date of Earliest Transaction (MM/DD/YYYY) 8/18/2020
(Street) WESTBROOK, ME 04092 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	8/18/2020		M		1880	A	$53.185	51486	D
Common Stock	8/18/2020		M		1256	A	$79.54	52732	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right-to-buy)	$53.185	8/18/2020		M			1880	(1)	12/31/2023	Common Stock	1880	(3)	0	D
Incentive Stock Option (right-to-buy)	$79.54	8/18/2020		M			1256	(2)	2/13/2025	Common Stock	1256	(3)	0	D

Explanation of Responses:
(1)	Grant of option to buy 4,700 shares of Issuer common stock that vested in five annual installments beginning on January 1, 2015. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").
(2)	Grant of option to buy 628 shares of Issuer common stock that vested on February 14, 2020. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.
(3)	Not applicable.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
MCKEON BRIAN P ONE IDEXX DRIVE WESTBROOK, ME 04092			Executive VP & CFO

Signatures
/s/ Lily J. Lu, Attorney-in-Fact for Brian P. McKeon		8/20/2020
**Signature of Reporting Person		Date